agilon health, inc. (AGL): Results of Operations and Financial Condition
agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agl-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 agilon health Reports Second Quarter 2026 Results Revenue increase 7% to $1.49 billion Raises Full-Year 2026 Total Revenues, Medical Margin, and Adjusted EBITDA Guidance Westerville, O.H., August 5, 2026 – agilon hea
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY2026 guidance ranges and the Q2 profitability improvements (gross profit, medical margin, Adjusted EBITDA) versus the prior year period.
Market read
Guidance and profitability metrics are updated in a primary filing, creating a direct catalyst for earnings-model repricing.
What to watch
Medical margin includes favorable claims development, and ACO model entities are not consolidated, which can complicate GAAP-to-non-GAAP interpretation.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 operating results and revised FY2026 and Q3 2026 guidance.
Ticker impact
agilon health reported Q2 2026 results and raised full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
Likely positive near-term bias as guidance increases and Q2 profitability inflects, though member declines and ACO non-consolidation may temper upside.
The filing includes specific Q2 financial improvements and explicit updated FY2026 ranges for revenues, medical margin, and Adjusted EBITDA, which are direct valuation inputs for the stock.
Market effects
Provides a read-through on value-based care execution and medical cost trends for managed care and healthcare services peers.
Limited, primarily US healthcare services sentiment.
Low, company-specific US filing.
Counterpoint
Member counts declined (total members down 10% YoY), so the guidance raise may rely on cost and pricing improvements rather than sustained growth.
Key entities
- companyagilon health, inc.
Reported Q2 2026 results and increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
- executiveTim O’Rourke
CEO quoted on progress across strategic initiatives and confidence in the Total Care Model.
